Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells

Siglec-9 is an MHC-independent inhibitory receptor expressed on a subset of natural killer (NK) cells. Siglec-9 restrains NK cytotoxicity by binding to sialoglycans (sialic acid-containing glycans) on target cells. Despite the importance of Siglec-9 interactions in tumor immune evasion, their role as an immune evasion mechanism during HIV infection has not been investigated. Using in vivo phenotypic analyses, we found that Siglec-9+ CD56dim NK cells, during HIV infection, exhibit an activated phenotype with higher expression of activating receptors and markers (NKp30, CD38, CD16, DNAM-1, perforin) and lower expression of the inhibitory receptor NKG2A, compared to Siglec-9- CD56dim NK cells. We also found that levels of Siglec-9+ CD56dim NK cells inversely correlate with viral load during viremic infection and CD4+ T cell-associated HIV DNA during suppressed infection. Using in vitro cytotoxicity assays, we confirmed that Siglec-9+ NK cells exhibit higher cytotoxicity towards HIV-infected cells compared to Siglec-9- NK cells. These data are consistent with the notion that Siglec-9+ NK cells are highly cytotoxic against HIV-infected cells. However, blocking Siglec-9 enhanced NK cells’ ability to lyse HIV-infected cells, consistent with the known inhibitory function of the Siglec-9 molecule. Together, these data support a model in which the Siglec-9+ CD56dim NK subpopulation is highly cytotoxic against HIV-infected cells even whilst being restrained by the inhibitory effects of Siglec-9. To harness the cytotoxic capacity of the Siglec-9+ NK subpopulation, which is dampened by Siglec-9, we developed a proof-of-concept approach to selectively disrupt Siglec/sialoglycan interactions between NK and HIV-infected cells. We achieved this goal by conjugating Sialidase to several HIV broadly neutralizing antibodies. These conjugates selectively desialylated HIV-infected cells and enhanced NK cells’ capacity to kill them. In summary, we identified a novel, glycan-based interaction that may contribute to HIV-infected cells’ ability to evade NK immunosurveillance and developed an approach to break this interaction.

[1]  Z. Ball,et al.  Precision Modification of Native Antibodies. , 2021, Bioconjugate chemistry.

[2]  Zeru Tian,et al.  Synthesis of precision antibody conjugates using proximity-induced chemistry , 2021, Theranostics.

[3]  F. Kirchhoff,et al.  SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity , 2021, Nature Communications.

[4]  M. Betts,et al.  Phenotypic Characterization of SLex+ and CLA+ CD4+ T Cells , 2020, STAR protocols.

[5]  C. Bertozzi,et al.  Targeted glycan degradation potentiates the anticancer immune response in vivo , 2020, Nature Chemical Biology.

[6]  B. Liao,et al.  Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo , 2020, Nature.

[7]  J. Kim,et al.  Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge , 2019, Human vaccines & immunotherapeutics.

[8]  Daniel W. Kulp,et al.  In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. , 2019, The Journal of clinical investigation.

[9]  A. Varki,et al.  Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses , 2019, Cellular and Molecular Life Sciences.

[10]  M. O'Dwyer,et al.  Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer , 2019, Front. Immunol..

[11]  P. Romero,et al.  Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment , 2019, Cancer Immunology Research.

[12]  G. Nolan,et al.  Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control , 2019, Journal of Virology.

[13]  Juan Tang,et al.  Proximity-Induced Site-Specific Antibody Conjugation. , 2018, Bioconjugate chemistry.

[14]  C. Amos,et al.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells , 2018, The Journal of clinical investigation.

[15]  Lifen Gao,et al.  Decreased Siglec-9 Expression on Natural Killer Cell Subset Associated With Persistent HBV Replication , 2018, Front. Immunol..

[16]  Z. ZuluMichael,et al.  Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56−CD16+ Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection , 2017 .

[17]  B. Jacquelin,et al.  Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys , 2017, Nature Medicine.

[18]  J. Lifson,et al.  Defining total-body AIDS-virus burden with implications for curative strategies , 2017, Nature Medicine.

[19]  M. Rossetti,et al.  A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity. , 2017, Journal of visualized experiments : JoVE.

[20]  L. Montaner,et al.  HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects , 2017, Journal of viral hepatitis.

[21]  A. Varki,et al.  Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes , 2017, Scientific Reports.

[22]  L. Montaner,et al.  IFN-α augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. , 2017, AIDS.

[23]  Carolyn R Bertozzi,et al.  Precision glycocalyx editing as a strategy for cancer immunotherapy , 2016, Proceedings of the National Academy of Sciences.

[24]  R. Siliciano,et al.  Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.

[25]  T. D. de Gruijl,et al.  Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer , 2016, PloS one.

[26]  Nico Pfeifer,et al.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 , 2016, Science.

[27]  G. Alter,et al.  NK Cells in HIV Disease , 2016, Current HIV/AIDS Reports.

[28]  Rebecca Hoh,et al.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. , 2015, The lancet. HIV.

[29]  G. Pantaleo,et al.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.

[30]  M. Carrington,et al.  Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat , 2015, Journal of Virology.

[31]  C. Heyser,et al.  Siglec receptors impact mammalian lifespan by modulating oxidative stress , 2015, eLife.

[32]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[33]  D. Hazuda,et al.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. , 2014, The Journal of infectious diseases.

[34]  S. Ávila-Ríos,et al.  Activation of NK cells is associated with HIV‐1 disease progression , 2014, Journal of Leukocyte Biology.

[35]  P. Romero,et al.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. , 2014, The Journal of clinical investigation.

[36]  R. Siliciano,et al.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Maserati,et al.  Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages , 2013, Retrovirology.

[38]  Stephen M. Canham,et al.  Glycocalyx Engineering Reveals a Siglec-Based Mechanism for NK Cell Immunoevasion , 2013, Nature chemical biology.

[39]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[40]  D. Havlir,et al.  The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. , 2013, The Journal of infectious diseases.

[41]  S. Boni,et al.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation , 2013, Proceedings of the National Academy of Sciences.

[42]  R. Siliciano,et al.  HIV-1 eradication strategies: design and assessment , 2013, Current opinion in HIV and AIDS.

[43]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[44]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[45]  A. Varki,et al.  Multifarious roles of sialic acids in immunity , 2012, Annals of the New York Academy of Sciences.

[46]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[47]  C. Rancourt,et al.  Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes , 2010, Molecular Cancer.

[48]  D. Nixon,et al.  Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. , 2009, Blood.

[49]  A. Moretta,et al.  The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. , 2009, Blood.

[50]  L. Montaner,et al.  NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.

[51]  Ajit Varki,et al.  Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.

[52]  D. Venzon,et al.  A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.

[53]  A. Fauci,et al.  Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  F. Lopez,et al.  The Membrane-Proximal Immunoreceptor Tyrosine-Based Inhibitory Motif Is Critical for the Inhibitory Signaling Mediated by Siglecs-7 and -9, CD33-Related Siglecs Expressed on Human Monocytes and NK Cells1 , 2004, The Journal of Immunology.

[55]  James C Paulson,et al.  Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9* , 2004, Journal of Biological Chemistry.

[56]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[57]  P. Crocker,et al.  Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes* , 2000, The Journal of Biological Chemistry.

[58]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[60]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[61]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[62]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[63]  L. Montaner,et al.  IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation. , 2017, AIDS.

[64]  Mahendra Kumar,et al.  Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: Quantification using real-time reverse transcriptase-polymerase chain reaction , 2011, Journal of NeuroVirology.

[65]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[66]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.